Episode 11
Imugene forges ahead with VAXINIA trial targeting solid tumours
Clinical-stage immuno-oncology biotech Imugene has been making significant strides in the development of therapies targeting a range of cancers. In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA).
November 3, 20238m 42s
Audio is streamed directly from the publisher (cdn.simplecast.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Clinical-stage immuno-oncology biotech Imugene has been making significant strides in the development of therapies targeting a range of cancers. In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA).